Breaking News
February 23, 2018 - Patients who achieve short-term weight loss before bariatric surgery have better outcomes
February 23, 2018 - Beetroot may reduce kidney failure risk after heart x-ray, research reveals
February 23, 2018 - Sleep disruptions in menopause correlated with hot flashes and depression
February 23, 2018 - Scientists discover new treatment approach to curb severe myocarditis
February 23, 2018 - ‘Click chemistry’ approach may improve disease-fighting properties of drugs
February 23, 2018 - NIGHTSEA and EMS team up to offer KEY Award in fluorescence stereo microscopy
February 23, 2018 - Tobacco Kills, No Matter How It’s Smoked: Study
February 23, 2018 - Q&A: Avindra Nath, MD | Medpage Today
February 23, 2018 - Adherence to sleep apnea treatment affects risk of hospital readmission
February 23, 2018 - Zika virus could be alternative for treatment of aggressive brain cancer
February 23, 2018 - Carbon monoxide enhances efficacy of antibiotic against stomach infection
February 23, 2018 - MSD and Ferring Pharmaceuticals Complete Largest Ever Clinical Trial in Postpartum Haemorrhage
February 23, 2018 - Portable ultrasound can help better detect fluid in the lungs of patients with end-stage kidney disease
February 23, 2018 - Postnova AF2000 system offers reliable characterization of trace metal colloid distribution in the environment
February 23, 2018 - Pioneering study may pave way for effective painkillers to treat neuropathic pain
February 23, 2018 - Research opens up new avenue to minimize risks of transplants
February 22, 2018 - Cabozantinib Active in Advanced Thyroid Cancer
February 22, 2018 - Polluted air may pollute our morality
February 22, 2018 - New data from VOYAGE 2 trial shows promising results for Janssen’s guselkumab treatment
February 22, 2018 - Bank loans signed in the hospital leave patients vulnerable
February 22, 2018 - Researchers identify new nanostructure inside sperm tails
February 22, 2018 - Catheter-based procedure increases treatment options for mitral valve disease
February 22, 2018 - Sage Therapeutics Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder
February 22, 2018 - Larger Endocarditis Vegetations More Likely to Embolize, Kill
February 22, 2018 - Parenting behavior in adoptive families
February 22, 2018 - Researchers discover new weakness in sleeping sickness parasites
February 22, 2018 - Research project aims to find new ways to identify and treat most aggressive brain cancers
February 22, 2018 - Researchers explore how people with Alzheimer’s disease use end-of-life medical services
February 22, 2018 - Stroke survivors and carers feel marginalized due to lack of support from primary care
February 22, 2018 - Neuroscientists discover novel mechanism of action behind schizophrenia
February 22, 2018 - After shooting, ‘honor how kids want to deal with their feelings’
February 22, 2018 - U.S., EU and Japan Health Authorities Accept Regulatory Submissions For Review Of Pfizer’s Third-generation ALK Inhibitor Lorlatinib
February 22, 2018 - At-Home Genetic Test Might Change Medicine
February 22, 2018 - Many second hand plastic toys could pose a risk to children’s health, study suggests
February 22, 2018 - Study shows that two different brain systems cooperate during learning
February 22, 2018 - Liquefied brain tissue after stroke may harm surviving brain, UA study finds
February 22, 2018 - New intervention improves communication behaviors in couples affected by dementia
February 22, 2018 - Clinical trial shows safety of promising TSRI stroke drug
February 22, 2018 - Researchers discover new interaction mechanism of unstructured proteins
February 22, 2018 - A Patient’s Journey: Can I Kill the Glucose Monster?
February 22, 2018 - The Problem That Piles Up
February 22, 2018 - Kids can roll up their sleeves—again—for mumps protection
February 22, 2018 - Scientists find significant amounts of toxic metals in e-cigarette vapors
February 22, 2018 - 3D Signatures reports positive results of new Telo-HL test for Hodgkin’s lymphoma
February 22, 2018 - Scientists reveal development of improved medicine to fight addiction
February 22, 2018 - USC-led researchers release dataset of brain scans from stroke patients
February 22, 2018 - Antibiotic-producing bacterium releases more metabolites than assumed
February 22, 2018 - Flu Season Shows First Signs of Slowing
February 22, 2018 - Nonstick Chemicals May Disrupt Metabolic Function in Women
February 22, 2018 - Calcium may play a role in the development of Parkinson’s disease
February 22, 2018 - Scientists visualize insulin receptor activation for the first time
February 22, 2018 - UC San Diego Health now offers new treatment option for people with refractory epilepsy
February 22, 2018 - First African child vaccinated with new typhoid conjugate vaccine
February 22, 2018 - BetterYou named as ‘Most Innovative Brand’ at FGB Awards 2018
February 22, 2018 - Assaults Among Young People Fall to Lowest Rate in 15 Years
February 22, 2018 - What do you know about Parkinson’s disease?
February 22, 2018 - Researchers discover five new genetic changes that may increase pancreatic cancer risk
February 22, 2018 - Gout medication may help improve heart function in adult patients
February 22, 2018 - Bioactive compound limits collateral damage in the kidneys after heart attack
February 22, 2018 - Study reveals HCT as effective treatment for NHL patients regardless of age
February 22, 2018 - Father’s age can affect offspring lifespan, mice study shows
February 22, 2018 - Opiant Pharmaceuticals Announces Publication of New Pre-Clinical Data Supporting Potential of OPNT005 as a Heroin Vaccine
February 22, 2018 - Make the Diagnosis: Strange Rash Surfaces
February 22, 2018 - Isolated sulfite oxidase deficiency – Genetics Home Reference
February 22, 2018 - Scientists identify weight loss ripple effect
February 22, 2018 - Smoking at record lows in New York
February 22, 2018 - Scientists pinpoint fertility hormone that could support early pregnancy
February 22, 2018 - Aggressive cancer stem cells can now be isolated successfully in a scientific breakthrough
February 22, 2018 - Researchers find high risk of suicide among unaccompanied refugee minors
February 22, 2018 - Protein levels linked to posture and gait problems in Parkinson’s
February 22, 2018 - Biomedical engineers create 3D hydrogel scaffolds  to transform cells into muscle
February 22, 2018 - Study employs novel approach to uncover new biomarker for CHD
February 22, 2018 - Study finds strong connection between midwifery and birth outcomes
February 22, 2018 - Verastem Submits NDA to FDA for Duvelisib for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma
February 22, 2018 - Low BP Associated With Risk in HFpEF
February 22, 2018 - More U.S. women obese before pregnancy, experts sound the alarm
February 22, 2018 - Study aims to examine effects of PTSD symptoms in police officers
February 22, 2018 - Study reveals increased disease risk after early heart surgery
February 22, 2018 - Women with Type 1 diabetes come across unique challenges
February 22, 2018 - Researchers target abnormal epigenetic mechanisms involved in childhood cancers
Patients with rare diseases and congress square off over orphan drug tax credits

Patients with rare diseases and congress square off over orphan drug tax credits

image_pdfDownload PDFimage_print

Taking the credit away, Taylor said, “eliminates the possibility for my child to have a bright and happy future.”

Taylor, whose 9-year-old son, Aiden, has a rare connective tissue disorder, spoke as part of a small rally thrown together this week by the National Organization for Rare Disorders (NORD) — the nation’s largest advocacy group for patients with rare diseases.

Earlier this month, House Republicans proposed eliminating the orphan drug tax credits, which Congress passed as part of a basket of financial incentives for drugmakers in the 1983 Orphan Drug Act. The law, intended to spur development of medicines for rare diseases, also gives seven years of market exclusivity for drugs that treat a specific condition that affects fewer than 200,000 people.

The Senate Finance Committee, led by Sen. Orrin Hatch (R-Utah), put the tax credit back into the tax legislation. After some negotiations, the committee settled on reducing the credit to 27.5 percent of the costs of preapproved clinical research, compared with the current 50 percent. The committee also restored a provision that would have eliminated any credits for drugmakers who repurpose a mass-market drug as an orphan.

“As with any major reform, tough choices have to be made,” a Hatch spokesperson wrote in an emailed statement, adding that the senator will continue to work “to make the appropriate policy decisions” to deliver a comprehensive tax overhaul.

Hatch, a member of a rare-disease congressional caucus, received $102,600 in campaign contributions from pharmaceutical and related trade group political action committees in the first half of 2017, making him the top recipient of pharmaceutical cash in the Senate.

If the Senate provision remains untouched, reducing the tax credit would save the federal government nearly $30 billion over a decade, according to a markup of the bill released late last week.

Orphan drug development has become big business in recent years and advocates as well as critics of the industry say tax credits have been an important motivation for companies. Orphan drugs accounted for 7.9 percent of total U.S. drug sales last year, according to a report released by QuintilesIMS and NORD.

Because patient populations for rare-disease drugs are relatively small, companies often charge premium prices for the medicines. EvaluatePharma, a company that analyzes the drug industry, estimates that among the top 100 drugs in the U.S. the average annual cost per patient for an orphan drug last year was $140,443. Giant pharmaceutical companies such as Celgene, Roche, Novartis, AbbVie and Johnson & Johnson have led worldwide sales in the orphan market, according to EvaluatePharma’s 2017 Orphan Drug Report.

Jonathan Gardner, the U.S. news editor for EvaluatePharma, said the orphan drug tax credit is “probably the most important incentive for developing an orphan drug.” Cutting the credit will force even the large companies to question development of drugs for rare diseases, Gardner said.

Dr. Aaron Kesselheim, an associate professor of medicine at Harvard Medical School, has been critical of the Orphan Drug Act’s incentives and of companies taking advantage of the law’s financial incentives for profit. But he warned against rushing to eliminate the tax credit.

“We need to think about ways we can improve the Orphan Drug Act and stop people from gaming the system and exploiting it,” Kesselheim said. But there “are a lot of rare diseases that don’t have treatments. So, we need to be careful in making changes.”

The battle over the tax credit is the latest controversy for the Food and Drug Administration’s orphan drug program. FDA Commissioner Scott Gottlieb announced a “modernization” plan for the agency this summer, closing a pediatric testing loophole and eliminating a backlog of corporate applications for orphan drug status. And, this week, the agency confirmed that Dr. Gayatri Rao, director for the Office of Orphan Products Development, is leaving.

Meanwhile, the Government Accountability Office confirmed this month that it recently launched an investigation of the orphan drug program. The GAO’s review was sparked by a letter from top Republican Sens. Hatch, Chuck Grassley (R-Iowa) and Tom Cotton (R-Ark.), asking the agency to investigate whether drugmakers “might be taking advantage” of the drug approval process.

When the 1983 Orphan Drug Act was passed, the law described an orphan drug as one that affects so few people that drugmakers might lose money after covering the cost of developing a drug. Congress added the 200,000-patient limit in 1984.

Today, many orphan medicines treat more than one condition and often come with astronomical prices. Many of the medicines aren’t entirely new, either. A Kaiser Health News investigation, which was also aired and published by NPR, found that more than 70 of the roughly 450 individual drugs given orphan status were first approved for mass-market use, including cholesterol blockbuster Crestor, Abilify for psychiatric conditions, cancer drug Herceptin and rheumatoid arthritis drug Humira, which for years was the best-selling medicine in the world.

More than 80 other orphans won FDA approval for more than one rare disease and, in some cases, multiple rare diseases, the KHN investigation showed.

The pharmaceutical industry has had a muted response to the tax bill, which includes a corporate tax cut. The powerful industry lobbying group PhRMA said it is pleased Congress is looking at overhauling the tax code but “encourages policymakers to maintain incentives” for rare diseases. BIO, the Biotechnology Innovation Organization that represents biomedical companies, said it was “gratified” the Senate committee chose to partially retain the credit but would prefer to keep the existing incentive.

The group that rallied Tuesday — wearing bright-orange shirts that read “Save the Orphan Drug Tax Credit” — planned to meet with a couple of dozen lawmakers, including Grassley, who is a member of the Senate Finance Committee.

NORD, like many patient advocacy groups, receives funding from pharmaceutical companies, but the organization’s leaders say the industry does not have members on the board and does not dictate how general donations are spent.

On Tuesday, NORD leaders said they are open to discussions about the tax credit and whether the overall law is working as intended.

“We’re here to have that conversation, we’re ready to have that conversation,” said Paul Melmeyer, director of federal policy for NORD. “Sadly, that’s not the conversation we are having today.”

Abbey Meyers, a founder of NORD and the leading advocate behind passing the initial 1983 law, said she fears the high cost of the drugs will make it impossible to sustain the orphan drug program. Now retired, Meyers said she has followed the law’s success over the years and believes the tax credit should not be changed.

“There are other things that have happened since the law was passed where there wasn’t any logic to what they did,” Meyers said, adding “because somebody went to a senator and they put into the law.”

KHN’s coverage of prescription drug development, costs and pricing is supported by the Laura and John Arnold Foundation. Kesselheim’s work is also supported by the foundation.


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Tagged with:

About author

Related Articles